Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer Vaccine
Lapatinib with anti-ErbB2 antibodies enhances breast cancer cell apoptosis
November 10th, 2005
Combining lapatinib, a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells. "Antibodies and small molecule tyrosine kinase inhibitors targeting ErbB2 exhibit distinct, noncross resistant mechanisms of action. Here, apoptosis of ErbB2-over-expressing breast cancer cells was enhanced by combining lapatinib, an inhibitor of ErbB1 and ErbB2 tyrosine kinases, with anti-ErbB2 antibodies, including trastuzumab, a humanized monoclonal antibody; and pAb, rabbit polyclonal antisera generated by vaccination with a human ErbB2 fusion protein," scientists in the United...
Source: Women's Health Weekly (2005-11-10)
|
